#PHA The price is moving in a bearish channel pattern on a 12-hour frame, which it adheres to perfectly. We have stability above the moving average of 100. We have a downtrend on the RSI indicator that supports the rise and is about to break higher Entry price is 0.2444 The first target is 0.2724 The second target is 0.3228 The third target is 0.3650
Achyut Healthcare Ltd is a pharmaceutical trading company that was established in 1996 and is based in Ahmedabad, Gujarat. The company trades in pharmaceutical products, medical devices, and APIs. It manufactures tablets, capsules, oral liquids, and injectables, and also customizes products for domestic and international markets. looking for 59 price in upcoming...
Eli Lilly aka LLY hit a new all time high again on Wednesday after rival GLP1 drugmaker Novo Nordisk announced it was ending a kidney failure study early for its drug semaglutide due to efficacy data. Shares of Lilly set a 52 week high of $608.7 before closing the session 5% higher at $605.28. Shares of Novo Nordisk increased as well, rising 6% to settle at...
Accumulation followed by Huge Volume . Cup & Handle pattern visible in Weekly TF. Good for Short Term. Target 160 ,200. Disclaimer : This is not a Buy or Sell recommendation. I am not SEBI Registered. Please consult your financial advisor before making any investments . This is for Educational purpose only.
Gilead Sciences (GILD): NASDAQ:GILD We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at...
So funny and amazing, when you had prepared a long-term vision for a company just 2 days ago, but did not published for a while, and purely by chance get notices, that this company has grown today for almost 250% in some hours. So, nevertheless, this only confirmed, that signals, which were seen are correct and I still can publish my forecast for almost 10...
On the 12 month timeframe, or yearly supercycle, ILMN seems to be consolidating enough these first 3 months into 2024 to ultimately flip to the upside with maximum bull force. The company has a solid catalyst with AI facilitating the end goal of a super biopharma product that perhaps all humanity may have to rely on: a panacea. This panacea may come in the form of...
momentum stock stabilising . lets see if it can fly
ALKEM is Near all time high Alkem is in a Rising channel and Resistance is working from last 8 years Stock is facing resistance around 5500 for the further upside Stock need to cross 5500 If stock tanks then we might see level of 3100-3200 3100-3200 is strongest support and one should not miss opportunity to BUY around these levels. Thank You...
Introduction Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is at the forefront of developing innovative cancer treatments, with a keen focus on leveraging their proprietary switch-control kinase inhibitor platform. The company has made significant strides, particularly with its flagship product, QINLOCK, and the promising pipeline candidate vimseltinib, aiming...
ATH Breakout. Rounding Bottom Structure. Good for Short term and Long term. Disclaimer : This is not a Buy or Sell recommendation. I am not SEBI Registered. Please consult your financial advisor before making any investments . This is for Educational purpose only.
Axsome Therapeutics - NASDAQ:AXSM ▫️ Entered a position in Oct 2022 on the bounce off the 200 week SMA (averaging $50.77c per share) ▫️ That position is presently in 73% profit ▫️ I have no intention of selling at present as we have a strong underside support from the 200 week MA, the 200 day MA and high volume trading zone from $70-78. ▫️ This a longer term...
Eli Lilly - NYSE:LLY Earnings Rep: $2.49 ✅ Exp: $2.29 - 8.45% HIGHER Revenue Rep: $9.35b ✅ Exp: $8.94b - 4.55% HIGHER Company Summary Eli Lilly is the worlds 9th largest company by market cap at $670b and they have reported positive earnings and revenue both coming in higher than expected for Q4 2023. The pharmaceutical giant booked fourth-quarter...
Entry - at 398 or 417 SL - 3% at both entries TGT - 520+
Entry Possible above 950 level SL - 720 Short term Target - 1190 Long term Target - 1500 Disclaimer - All information on this page is for educational purposes only, we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you...
A short two minute overview of Biocon and levels to watch. Before taking any trade please do your own research. This is only an insight from us thank you
as you can see this could be a huge Symmetrical triangle, like in the case of Bitcoin and S&P this means a change of trend, and a potential 120%